Company intelligence / Profile preview
OnQuality Pharmaceuticals
Seattle, Washington, United Statesonqualityrx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
OnQuality's lead compound OQL011 is in Phase 2 clinical trials for Hand-Foot Skin Reaction. OQL051, a gut-restricted CDK4/6 inhibitor for chemotherapy-induced diarrhea, received FDA IND clearance in 2023. OQL036 for capecitabine-induced hand-foot syndrome also received FDA clinical clearance in 2023.
- Therapeutic areas
- GastroenterologyOncologyDermatology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on OnQuality Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OnQuality Pharmaceuticals.